Vandermeers A, Gourlet P, Vandermeers-Piret M C, Cauvin A, De Neef P, Rathe J, Svoboda M, Robberecht P, Christophe J
Eur J Biochem. 1987 Apr 15;164(2):321-7. doi: 10.1111/j.1432-1033.1987.tb11061.x.
Having previously isolated helodermin, the major peptide like vasoactive-intestinal-peptide and peptide-histidine-isoleucinamide, from the venom of the lizard Heloderma suspectum, we decided on a systematic exploration of all (VIP-PHI)-like peptides present in the venom of another lizard of the Helodermatidae family: Heloderma horridum. Six (VIP-PHI)-like peptides (PHH1 to 6) were purified to homogeneity from the venom of the lizard H. horridum with PHH3 and PHH4 representing two minor forms. All peptides cross-reacted in radioimmunoassays for helodermin and PHI but not for VIP. They yielded four fragments (T1 to T4) after trypsin digestion. T1, T2 and T3 showed the same retention time by reverse-phase HPLC and the same amino acid composition; the differences were confined to T4, the C-terminal sequence. PHH5 and PHH6 were found to be identical to synthetic helospectins I and II respectively. PHH1 and PHH3 probably resulted from a secondary modification of PHH5, while PHH2 and PHH4 derived from PHH6. Thus, the VIP-like peptides, previously called helospectins, are in fact typical of H. horridum venom. We confirmed that helodermin is the major (VIP-PHI)-like peptide of the venom of H. suspectum and observed its absence in H. horridum venom. Also, we found that positions 8 and 9 of helodermin are occupied by two Glu residues instead of two Gln as previously published. Helospectin-like material was also present in H. suspectum venom but in very small amount. In both venoms all VIP-like peptides were equally potent and efficient when tested for (a) their ability to occupy VIP as well as secretin receptors in rat pancreatic membranes and VIP receptors in rat liver membranes, and (b) the ensuing activation of adenylate cyclase in both membrane preparations.
我们之前已从可疑希拉毒蜥(Heloderma suspectum)的毒液中分离出了希拉毒蜥肽(helodermin),这是一种主要的、类似血管活性肠肽和肽组氨酸异亮氨酸酰胺的肽。之后,我们决定对希拉毒蜥科(Helodermatidae)另一种蜥蜴——墨西哥毒蜥(Heloderma horridum)毒液中存在的所有类血管活性肠肽-肽组氨酸异亮氨酸酰胺(VIP-PHI)肽进行系统研究。从墨西哥毒蜥的毒液中纯化出了六种类VIP-PHI肽(PHH1至6),使其达到均一状态,其中PHH3和PHH4代表两种次要形式。所有肽在针对希拉毒蜥肽和肽组氨酸异亮氨酸酰胺的放射免疫分析中发生交叉反应,但对血管活性肠肽不发生交叉反应。经胰蛋白酶消化后,它们产生了四个片段(T1至T4)。T1、T2和T3通过反相高效液相色谱显示出相同的保留时间和相同的氨基酸组成;差异仅限于C末端序列T4。发现PHH5和PHH6分别与合成的希拉毒蜥肽I和II相同。PHH1和PHH3可能是PHH5的二级修饰产物,而PHH2和PHH4源自PHH6。因此,之前被称为希拉毒蜥肽的类血管活性肠肽实际上是墨西哥毒蜥毒液所特有的。我们证实希拉毒蜥肽是可疑希拉毒蜥毒液中主要的类VIP-PHI肽,并观察到其在墨西哥毒蜥毒液中不存在。此外,我们发现希拉毒蜥肽的第8和9位被两个谷氨酸残基占据,而不是如先前发表的数据那样被两个谷氨酰胺占据。类希拉毒蜥肽物质也存在于可疑希拉毒蜥的毒液中,但含量极少。在两种毒液中,当测试所有类血管活性肠肽(a)占据大鼠胰腺膜中血管活性肠肽以及促胰液素受体和大鼠肝膜中血管活性肠肽受体的能力,以及(b)在两种膜制剂中随后激活腺苷酸环化酶的能力时,它们的效力和效率是相同的。